Home › NDC Lookup › RxCUI directory › RxCUI 1244616

Tafluprost 0.015 MG/ML Ophthalmic Solution [Zioptan] — RxCUI 1244616

RxNorm drug concept · Semantic branded drug
RxCUI 1244616 Semantic branded drug · SBD ● Current RxNorm concept 1 FDA product 1 package NDC Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI1244616
Official nameTafluprost 0.015 MG/ML Ophthalmic Solution [Zioptan]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asZioptan 0.0015 % Ophthalmic Solution; Zioptan 0.0045 MG in 0.3 ML Ophthalmic Solution; Zioptan 0.015 MG/ML Ophthalmic Solution
FDA products mapped1
Package NDCs mapped1
Reported Medicaid activity (SDUD)442 prescriptions · 7 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Tafluprost Ophthalmic: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • The evening timing isn't just a suggestion — studies show tafluprost works best when used at night, with its peak pressure-lowering effect hitting around 12 hours after you apply i...
  • Why do I have to use this drop in the evening specifically?
  • It can, yes — and this is one of the most important things to know. Tafluprost can gradually increase the brown pigment in your iris, which may darken the color of your eye over mo...
  • Will this drug change the color of my eyes?
📖 Read our full Tafluprost Ophthalmic guide →

🕸️ Concept Web — How Tafluprost 0.015 MG/ML Ophthalmic Solution [Ziop... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Tafluprost 0.015 MG/ML Ophthalmic Solution [Zioptan] RxCUI 1244616

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Tafluprost 1244607
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Zioptan 1244612
  3. Dose forms 6

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Tafluprost Ophthalmic Solution 1244610
    • Tafluprost Ophthalmic Product 1244609
    • Tafluprost Ophthalmic Solution [Zioptan] 1244614
    • Zioptan Ophthalmic Product 1244615
    • Ophthalmic Solution 7670
    • Ophthalmic Product 1151135
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 11 of 11 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

Brand-Name Concepts

  • Tafluprost 0.015 MG/ML [Zioptan] SBDC · 1244613
  • Tafluprost Ophthalmic Solution [Zioptan] SBDF · 1244614
  • Zioptan Ophthalmic Product SBDG · 1244615
  • Zioptan BN · 1244612

📦 FDA Products & Package NDCs

1 product · 1 package NDC
1 package NDC map to RxCUI 1244616 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
82584-0609-30 3 POUCH in 1 CARTON (82584-609-30) / 10 VIAL, SINGLE-USE in... ZIOPTAN Thea Pharma Inc. 2022-10-28
Observed labelers: Thea Pharma Inc. (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

💲 Pricing (NADAC)

NADAC is CMS's National Average Drug Acquisition Cost — roughly what pharmacies pay to buy the drug. It is an acquisition benchmark, not your copay.
Per ea · median
$8.4944
Range $8.4944–$8.4944 · middle 50% $8.4944–$8.4944 · 1 NDCs
Latest compatible distributions from the CMS NADAC file · dataset watermark 2026-07-10. Prices vary by package and pharmacy; a distribution is shown instead of one misleading number. Rows the dataset is silent on carry no price. No zero-cost conclusion should be drawn.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.